glp-1 receptor agonist type 1 diabetes trial liraglutide agonists in the treatment of 2 – state-of-the-art Glucagon-like peptide-1 receptor agonists (GLP-1RAs)

The evidence suggests that without deliberate intervention, patients on GLP-1 therapies may lose a significant proportion of their weight from lean mass, a finding that has considerable implications for long-term metabolic health, physical function, and the sustainability of results. Why Muscle Mass is Not a Cosmetic Concern When patients hear the phrase muscle loss, they frequently interpret it through an aesthetic lens

To obtain the right starting material, tons of intestines (figure 18) had to be rapidly boiled in large water-vapour-heated tanks, following which they needed to be minced and then extracted in acetic acid

Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data

Heerspink HJL, Sattar N, Pavo I et al (2022) Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Alongside further clinical trials would benefit in learning about the role of GLP-1RA in gestational diabetes and implications on fetal and placental diseases

doi:10.3390/cells9030740 178